Orthopaedic and Traumatology Unit, Ospedale Regionale di Lugano, EOC, Lugano, Ticino, Switzerland.
Applied and Translational Research Center, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Cartilage. 2021 Dec;13(1_suppl):185S-196S. doi: 10.1177/1947603520906597. Epub 2020 Mar 18.
To quantify the placebo effect of intraarticular injections for knee osteoarthritis in terms of pain, function, and objective outcomes. Factors influencing placebo effect were investigated.
Meta-analysis of randomized controlled trials; Level of evidence, 2. PubMed, Web of Science, Cochrane Library, and grey literature databases were searched on January 8, 2020, using the string: . The following inclusion criteria were used: double-blind, randomized controlled trials on knee osteoarthritis, including a placebo arm on saline injections. The primary outcome was pain variation. Risk of bias was assessed using the RoB 2.0 tool, and quality of evidence was graded following the GRADE (Grading of Recommendations Assessment, Development and Evaluation) guidelines.
Out of 2,363 records, 50 articles on 4,076 patients were included. The meta-analysis showed significant improvements up to the 6-month follow-up: Visual Analogue Scale (VAS)-pain -13.4 mean difference (MD) (95% confidence interval [CI]: -21.7/-5.1; < 0.001), Western Ontario and McMaster Osteoarthritis Index (WOMAC)-pain -3.3 MD (95% CI: -3.9/-2.7; < 0.001). Other significant improvements were WOMAC-stiffness -1.1 MD (95% CI: -1.6/-0.6; < 0.001), WOMAC-function -10.1 MD (95% CI: -12.2/-8.0; < 0.001), and Evaluator Global Assessment -21.4 MD (95% CI: -29.2/-13.6; < 0.001). The responder rate was 52% (95% CI: 40% to 63%). Improvements were greater than the "minimal clinically important difference" for all outcomes (except 6-month VAS-pain). The level of evidence was moderate for almost all outcomes.
The placebo effect of knee injections is significant, with functional improvements lasting even longer than those reported for pain perception. The high, long-lasting, and heterogeneous effects on the scales commonly used in clinical trials further highlight that the impact of placebo should not be overlooked in the research on and management of knee osteoarthritis.
从疼痛、功能和客观结果方面量化膝关节骨关节炎关节内注射的安慰剂效应。研究了影响安慰剂效应的因素。
随机对照试验的荟萃分析;证据水平,2 级。于 2020 年 1 月 8 日在 PubMed、Web of Science、Cochrane 图书馆和灰色文献数据库中使用字符串: 进行检索。纳入标准为:膝关节骨关节炎的双盲、随机对照试验,包括盐水注射的安慰剂臂。主要结局为疼痛变化。使用 RoB 2.0 工具评估偏倚风险,并根据 GRADE(推荐评估、制定与评价)指南对证据质量进行分级。
在 2363 条记录中,有 50 篇文章涉及 4076 名患者被纳入。荟萃分析显示,在 6 个月的随访中,疼痛有显著改善:视觉模拟评分(VAS)疼痛 -13.4 均数差(MD)(95%置信区间[CI]:-21.7/-5.1; < 0.001),西部安大略省和麦克马斯特大学骨关节炎指数(WOMAC)疼痛 -3.3 MD(95%CI:-3.9/-2.7; < 0.001)。其他显著改善的指标还有 WOMAC 僵硬 -1.1 MD(95%CI:-1.6/-0.6; < 0.001),WOMAC 功能 -10.1 MD(95%CI:-12.2/-8.0; < 0.001)和评估者总体评估 -21.4 MD(95%CI:-29.2/-13.6; < 0.001)。应答率为 52%(95%CI:40%~63%)。除 6 个月的 VAS 疼痛外,所有结局的改善均大于“临床最小重要差异”。几乎所有结局的证据水平均为中级。
膝关节注射的安慰剂效应显著,功能改善持续时间甚至长于疼痛感知的改善。在临床试验中常用的量表上,这种高、持久且异质性的效应进一步强调,在膝关节骨关节炎的研究和管理中,不应忽视安慰剂的影响。